SFX by Ex Libris Inc.

Title:	AIDS. Promote HIV chemoprophylaxis research, don't prevent it
Source:	Science [0036-8075] Grant, R M yr:2005

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Karim, Quarraisha A. "Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women." Lancet 378.9787 (2011): 279-281.
description	2.	Gray, Peter H. "Caffeine citrate for very preterm infants: Effects on development, temperament and behaviour." Journal of paediatrics and child health 47.4 (2011): 167-172.
description	3.	Blower, S. "The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics." Proceedings of the National Academy of Sciences of the United States of America 105.28 (2008): 9835-9840.
description	4.	Liu, Y. "Preexposure prophylaxis for HIV: unproven promise and potential pitfalls." JAMA 296.7 (2006): 863-5.
description	5.	Steer, P. "High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial." Archives of disease in childhood. Fetal and neonatal edition 89.6 (2004): 499-503.
description	6.	Balain, M. "Management of apnoea and bradycardia in the newborn." Paediatrics and child health 24.1 (2013): 17-22.
description	7.	Picone, S. "Caffeine citrate: when and for how long. A literature review." Journal of Maternal - Fetal & Neonatal Medicine 25 Suppl 3.3 (2012): 11-14.
description	8.	Aranda, Jacob V. "Caffeine impact on neonatal morbidities." Journal of Maternal - Fetal & Neonatal Medicine 23.SUPPL. 3 (2010): 20-23.
description	9.	Bremner, J. n. "The nature of imitation by infants." Infant behavior & development 25.1 (2002): 65-67.
description	10.	Cowan, Ethan A. "Is preexposure prophylaxis ready for prime time use in HIV prevention research?" AIDS 28.3 (2013): 293-295.
description	11.	Celum, Jared M. "Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence." Current opinion in infectious diseases 25.1 (2012): 51-57.
description	12.	Okwundu, C. "Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals- A systematic review." AIDS research and human retroviruses 26.10 (2010).
description	13.	Anderson, Peter L. "Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection." Journal of antimicrobial chemotherapy 66.2 (2010): 240-250.
description	14.	Paxton, Harold W A. "Pre-exposure prophylaxis for HIV infection: what if it works?" The lancet (2007): 89-93.
description	15.	Funk, S. "The spread of awareness and its impact on epidemic outbreaks." Proceedings of the National Academy of Sciences of the United States of America 106.16 (2009): 6872-7.
description	16.	Jacob, Jesse T T. "Acute forms of tuberculosis in adults." The American journal of medicine 122.1 (2008): 12-7.
description	17.	Christou, P. "Cost-effective production of a vaginal protein microbicide to prevent HIV transmission." Proceedings of the National Academy of Sciences of the United States of America 105.10 (2008): 3727-3732.
description	18.	Poppen, P. "Women's use of dual methods of sexual self-protection." Women & health 30.2 (1999): 53-66.
description	19.	Velasco-Hernandez, J X X. "Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?" The Lancet infectious diseases 2.8 (2002): 487-493.
description	20.	Han, C. "Markov chain Monte Carlo methods for computing Bayes factors: A comparative review." Journal of the American Statistical Association 96.455 (2001): 1122-1132.